Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2013204875B2 - Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor - Google Patents
[go: Go Back, main page]

AU2013204875B2 - Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor - Google Patents

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Info

Publication number
AU2013204875B2
AU2013204875B2 AU2013204875A AU2013204875A AU2013204875B2 AU 2013204875 B2 AU2013204875 B2 AU 2013204875B2 AU 2013204875 A AU2013204875 A AU 2013204875A AU 2013204875 A AU2013204875 A AU 2013204875A AU 2013204875 B2 AU2013204875 B2 AU 2013204875B2
Authority
AU
Australia
Prior art keywords
antibodies
human anti
uses therefor
therefor
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013204875A
Other versions
AU2013204875A1 (en
Inventor
Rafi Ahmed
Francis J. Carr
Gordon J. Freeman
James P. Gregson
Timothy D. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Emory University
Original Assignee
Dana Farber Cancer Institute Inc
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009296392A external-priority patent/AU2009296392B2/en
Application filed by Dana Farber Cancer Institute Inc, Emory University filed Critical Dana Farber Cancer Institute Inc
Priority to AU2013204875A priority Critical patent/AU2013204875B2/en
Publication of AU2013204875A1 publication Critical patent/AU2013204875A1/en
Application granted granted Critical
Publication of AU2013204875B2 publication Critical patent/AU2013204875B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2013204875A 2008-09-26 2013-04-12 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor Active AU2013204875B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204875A AU2013204875B2 (en) 2008-09-26 2013-04-12 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61/100,534 2008-09-26
AU2009296392A AU2009296392B2 (en) 2008-09-26 2009-09-25 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
AU2013204875A AU2013204875B2 (en) 2008-09-26 2013-04-12 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2009296392A Division AU2009296392B2 (en) 2008-09-26 2009-09-25 Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

Publications (2)

Publication Number Publication Date
AU2013204875A1 AU2013204875A1 (en) 2013-05-09
AU2013204875B2 true AU2013204875B2 (en) 2016-05-12

Family

ID=

Similar Documents

Publication Publication Date Title
IL265397B (en) Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2310415B8 (en) Antibodies against fcrn and use thereof
ZA201001514B (en) Humanized anti-cxcr5 antibodies,derivatives thereof and their uses
KR101882034B1 (en) Methods, devices, and materials for metallization
AP2010005379A0 (en) Anti-TRKA antibodies and derivatives.
EP2668210A2 (en) Anti-kit antibodies and uses thereof
EP2527404A4 (en) Composition for ultraviolet ray-absorbable member, and ultraviolet ray-absorbable member comprising same
EP2558431A4 (en) Narrow psd hydraulic cement-scm blends, and methods for making same
WO2009006359A8 (en) Anti- mcp-1 antibodies, compositions, methods and uses
WO2011088272A9 (en) Selective ampd2 inhibitors and methods for using the same
AU2013204875B2 (en) Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
EP2576910A4 (en) Method, element and form
HK1167868A (en) Anti-egfr antibodies and their uses
HK1179984A (en) Anti-alpha2 integrin antibodies and their uses
HK1158506A (en) Anti-cd147 antibodies, methods, and uses
HK1165434A (en) Humanized anti-egfl7 antibodies and methods using same
HK1160147A (en) Antibodies directed to dll4 and uses thereof
AU2007902971A0 (en) Receptors and related methods and products
AU2011903005A0 (en) Sanitary disposal bags, and cream applicator for back
HK1137179A (en) Anti-robo4 antibodies and uses therefor
HK1188458A (en) Anti-sod1 antibodies and uses thereof
HK1158670A (en) Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
HK1163135A (en) Human antibodies against human tissue factor
HK1179536A (en) Cd20 antibodies and uses thereof